IP Library Granted Patent US 11,583,510
Granted Patent B1
US 11,583,510 · App. 17/666,205 · Granted Feb 21, 2023

Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Inventors: Julien Grassot (Lyons, FR); David Monteith (Lyons, FR); Hervé Guillard (Villeurbanne, FR); Claire Mégret (Lyons, FR); Jean-François Dubuisson (Lyons, FR)
Assignee: Flamel Ireland Limited
A61K31/19A61K9/1676A61K9/5015A61K9/5026A61K9/5042A61K9/5078A61K9/5084A61K31/22A61P25/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,583,510
App. No.
17/666,205
Granted
Feb 21, 2023
Kind
B1
Abstract

Provided herein are methods of administering a once-nightly dosage of gamma-hydroxybutyrate after a high-fat meal.

Claims (14)

1. A method of treating narcolepsy, cataplexy, or excessive daytime sleepiness in a human subject in need thereof, the method comprising orally administering to the subject a once-nightly dosage of a gamma-hydroxybutyrate formulation comprising an immediate release portion and a modified release portion, wherein oral administration immediately after a high-fat meal results in a mean reduction in C max of gamma-hydroxybutyrate by 33% and a T max of gamma-hydroxybutyrate that is approximately 1 h longer as compared to administering the once-nightly dosage in a fasted state.

2. The method of claim 1 , wherein mean C max in a fed state is 64.0 μg/mL.

3. The method of claim 1 , wherein fat comprises 50% of the total content of the high-fat meal.

4. The method of claim 1 , wherein the high-fat meal comprises 500-600 kcal derived from fat.

5. The method of claim 1 , wherein AUC inf is lower in a fed state as compared to a fasted state.

6. The method of claim 1 , further comprising advising the human subject that consumption of alcohol is contraindicated with the once nightly dosage and may result in a more rapid release of the gamma-hydroxybutyrate.

7. The method of claim 1 , wherein the modified release portion comprises microparticles comprising gamma-hydroxybutyrate.

8. The method of claim 1 , wherein the immediate release portion comprises microparticles comprising gamma-hydroxybutyrate.

9. A method of treating narcolepsy, cataplexy, or excessive daytime sleepiness in a human subject in need thereof, the method comprising orally administering a gamma-hydroxybutyrate formulation to the subject, wherein the administering occurs only once daily, and wherein oral administration of the formulation immediately after a high-fat meal results in a mean reduction in C max of gamma-hydroxybutyrate by 33% and an average Tmax increase of gamma-hydroxybutyrate from 0.5 hr to 1.5 hr as compared to administering the formulation in a fasted state.

10. The method of claim 9 , wherein mean C max of gamma-hydroxybutyrate in a fed state is 64.0 μg/mL.

11. The method of claim 9 , wherein fat comprises 50% of the total content of the high-fat meal.

12. The method of claim 9 , wherein the high-fat meal comprises 500-600 kcal derived from fat.

13. The method of claim 9 , wherein AUC inf is lower in a fed state as compared to a fasted state.

14. The method of claim 9 , further comprising advising the human subject that consumption of alcohol is contraindicated with the formulation and may result in a more rapid release of gamma-hydroxybutyrate.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 21, 2026
From: RTW INVESTMENTS, LP, AS COLLATERAL AGENT
To: AVADEL CNS PHARMACEUTICALS, LLC; FLAMEL IRELAND LTD.
Reel/Frame 074729/0205 →
PATENT COLLATERAL AGREEMENT Recorded Aug 1, 2023
From: AVADEL CNS PHARMACEUTICALS, LLC; FLAMEL IRELAND LTD.
To: RTW INVESTMENTS, LP
Reel/Frame 064463/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2022
From: GRASSOT, JULIEN; MONTEITH, DAVID; GUILLARD, HERVÉ; MÉGRET, CLAIRE; DUBUISSON, JEAN-FRANÇOIS
To: FLAMEL IRELAND LIMITED
Reel/Frame 059681/0788 →
Cited By (17)
US 1,141,397 US 12,186,296 US 12,186,298 US 12,226,377 US 12,226,388 US 12,226,389 US 12,239,625 US 12,257,223 US 12,263,150 US 12,263,151 US 12,295,926 US 12,303,478 US 12,337,066 US 12,396,956 US 12,478,604 US 12,551,457 US 12,691,090